Short answer
Danaher Corporation (DHR) filed its Q3 2025 10-Q quarterly report on Oct 21, 2025 for the quarter ended Sep 26, 2025. Quarterly revenue was $6.1B (up 4.4% year over year) with net income of $908M.
Q3 2025 key financials · XBRL
- Revenue
- $6.1B
- +4.4% YoY · +2.0% QoQ
- Net income
- $908M
- +11.0% YoY · +63.6% QoQ
- Operating margin
- 19.1%
- Gross margin
- 58.2%
- EPS (diluted)
- $1.27
- +13.4% YoY · +62.8% QoQ
Source: XBRL data from the Danaher Corporation (DHR) Q3 2025 10-Q on SEC EDGAR. USD.
Danaher Corporation Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $6.05B Q3 2025, up 4.5% YoY; Nine months $17.73B, up 2.5% YoY, driven by Biotechnology and Diagnostics growth
- Operating margin 19.1% Q3 2025 vs 16.5% YoY (+260 bps); Nine months margin 18.0% vs 19.8% YoY (-180 bps) due to impairments
- Best segment: Biotechnology sales $1.8B (+9.0% Q3), margin 19.6% vs 23.6% YoY; Worst: Life Sciences sales $1.79B (+0.5% Q3), margin 12.4% vs 2.0% YoY
- Operating cash flow $4.3B nine months, down 8%; cash $1.5B; capital expenditures $785M; reduced stock repurchases $3.1B from $5.2B prior year
- Tariff costs expected to rise by several hundred million in 2025; management expects to offset tariff impact but notes risks from supply chain and trade uncertainties
Risk Factors
- New trade policy risk due to U.S. tariffs and retaliatory tariffs impacting supply costs and pricing competitiveness
- Material update on tariffs includes August 2025 U.S. Court ruling against certain tariffs, pending U.S. Supreme Court review
- Regulatory risk from reshoring policies, especially China promoting local medical device development affecting global supply chains
- Operational risk from supply chain disruptions and product availability due to tariffs and export restrictions between U.S. and China
- Financial risk from margin pressure when higher import costs are not fully or immediately recoverable through price increases
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Danaher Corporation quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.